Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Fineline Cube Jan 11, 2026
Company Deals

Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push

Fineline Cube Jan 11, 2026
Company Deals

Takeda Licenses Halozyme’s ENHANZE Technology for Vedolizumab in Global Deal

Fineline Cube Jan 11, 2026
Company Deals

Eisai China and Xuanwu Hospital Forge Strategic Cooperation for Drug R&D

Fineline Cube Jan 11, 2026
Company Deals

InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform

Fineline Cube Jan 10, 2026
Policy / Regulatory

NMPA Issues New Rules to Strengthen Pharmaceutical Contract Manufacturing Oversight

Fineline Cube Jan 9, 2026
Company Drug

Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy

Fineline Cube Jan 11, 2026
Company Drug

RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo

Fineline Cube Jan 11, 2026
Company Drug

Novartis’ Scemblix Approved by NMPA for Newly Diagnosed Ph+ CML-CP Patients

Fineline Cube May 15, 2025

Swiss pharmaceutical company Novartis (NYSE: NVS) announced that it has received marketing approval from China’s...

Company Drug

AbbVie’s Emrelis Granted FDA Accelerated Approval for NSCLC with High c-MET Overexpression

Fineline Cube May 15, 2025

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to AbbVie’s (NYSE: ABBV)...

Company

BeiGene Announces Plans to Relocate Headquarters to Switzerland from Cayman Islands

Fineline Cube May 15, 2025

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), the China-based oncology company that has proposed...

Company Drug

Chengdu Kanghong’s KH607 Approved for Clinical Trials in Postpartum Depression

Fineline Cube May 15, 2025

China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd. (SHE: 002773) has announced that it has received...

Medical Device Policy / Regulatory

NMPA Releases Updated List of Medical Devices Exempted from Clinical Evaluation

Fineline Cube May 15, 2025

The National Medical Products Administration (NMPA) has released the latest version of the “List of...

Company Drug

Boehringer Ingelheim’s Nerandomilast Filing Accepted for Review in Progressive Pulmonary Fibrosis

Fineline Cube May 15, 2025

Boehringer Ingelheim announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products...

Company Drug

Novartis’ Kisqali Receives NMPA Approval for High-Risk Early Breast Cancer

Fineline Cube May 15, 2025

Switzerland-based Novartis (NYSE: NVS) announced this week that it has received another indication approval from...

Company Deals

MGI Tech Partners with Genoks to Enhance Clinical Testing Services in Türkiye

Fineline Cube May 15, 2025

China-based gene sequencing specialist MGI Tech Co., Ltd. (SHA: 688114) has entered into a strategic...

Company Deals

Jiangsu Hengrui Pharmaceuticals Launches Hong Kong IPO of H-Shares

Fineline Cube May 15, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has officially launched an initial public offering...

Company Deals

CSPC Pharma Licenses Irinotecan Liposome Injection to Cipla for US Market

Fineline Cube May 15, 2025

China-based CSPC Pharmaceutical Group Ltd. (HKG: 1093) has entered into a licensing agreement with India-headquartered...

Company Drug

WuHan Hamilton Biotech’s HUC-MSCs Product Approved for Clinical Trials in Premature Ovarian Failure

Fineline Cube May 15, 2025

China-based WuHan Hamilton Biotechnology Co., Ltd. has announced receiving clinical trial approval from the National...

Others

AbbVie Pays $335 Million Upfront to ADARx for Next-Gen siRNA Therapeutics

Fineline Cube May 15, 2025

US-based pharma giant AbbVie (NYSE: ABBV) has entered into a significant collaboration with ADARx Pharmaceuticals,...

Company Medical Device

Roche’s VENTANA MET (SP44) RxDx Assay Gains FDA Approval for NSQ-NSCLC Patients

Fineline Cube May 15, 2025

Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced that the FDA has approved the VENTANA®...

Company Deals

Novo Nordisk and Septerna Ink $2.2 Billion Deal for GPCR Drug Discovery

Fineline Cube May 15, 2025

Denmark-based Novo Nordisk (NYSE: NVO, CPH: NOVO-B) and Septerna, Inc. (NASDAQ: SEPN) announced an exclusive...

Company

Sanofi Announces $20 Billion Investment in US R&D and Manufacturing by 2030

Fineline Cube May 15, 2025

French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced its intention to invest at least $20...

Company Deals

GSK Signs Deal to Acquire Boston Pharmaceuticals’ Efimosfermin Alpha

Fineline Cube May 14, 2025

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) has entered into an agreement to acquire BP...

Company Deals

Acchrom Technologies Secures Pre-Series B Funding to Expand Chromatography Solutions

Fineline Cube May 14, 2025

Beijing-based Acchrom Technologies Co., Ltd., a specialist in chromatography, has reportedly secured over RMB 100...

Company Deals

Ningbo Jansen Files STAR IPO for MRI Technology Expansion

Fineline Cube May 14, 2025

China-based Ningbo Jansen NMR Technology Co., Ltd. announced that its initial public offering (IPO) filing...

Company Drug Medical Device

China’s Q1 2025 Pharmaceutical Exports Rise 4.39% Despite Import Decline

Fineline Cube May 14, 2025

The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)...

Company Deals

Porton Pharma Collaborates with Henan Hualong for MATC Therapy Development

Fineline Cube May 14, 2025

China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions Ltd has entered into a...

Posts pagination

1 … 102 103 104 … 606

Recent updates

  • Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market
  • Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push
  • Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy
  • RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo
  • Merck Initiates Phase 3 Trial for Calderasib + KEYTRUDA QLEX in KRAS G12C NSCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Company Deals

Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push

Company Drug

Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy

Company Drug

RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.